Eccogene Completes 180 Million CNY in Series B Round Financing

June, 2023,Eccogene (Shanghai) Co. Ltd. (Eccogene) announced that it has received 180 million yuan (approximately $25 million USD) in Series B financing. The financing was led by New Alliance Capital and Zhangke Herun Capital(张科禾润), with participation from
Rockbleu Capital, ROYAL fund, Huajin Capital, Elikon Venture and existing investors Delos Capital, Oriza Seed Capital and Tsingsong Capital.

According to the public information, the funds raised in this round will be used to support the company’s clinical-stage metabolic pipeline research and development, including the small molecule GLP-1 receptor agonist ECC5004 for the treatment of obesity and type 2 diabetes, as well as the THRβ full agonist ECC4703 for NASH and lipid disorders. It will also be for Eccogene’s preclinical project research and development in the areas of metabolic and immunological diseases.

Eccogene is a biopharmaceutical company that develops innovative treatments for metabolic and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science to advance its pipeline of drugs.Eccogene is dedicated to innovative drug discovery for metabolic and immune related diseases with full rights for pipelines are as follows:

• ECC5004, a once daily, low dose, small molecule GLP-1 receptor agonist (GLP-1RA) is currently in a US Phase I clinical trial in healthy participants and patients with type 2 diabetes (T2D); ECC5004 has been demonstrated in preclinical studies to possess desirable efficacy and a safety profile with the potential to be the best-in-class GLP-1RA
• ECC4703, a THRβ full agonist, which is currently in a
  US Phase I trial in healthy participants and subjects with elevated LDL; ECC4703 has demonstrated superiority over partial agonist MGL-3196 in pre-clinical studies. It has also shown robust efficacy in pre-clinical models of NASH and dyslipidemia
• ECC0509, a peripherally distributed SSAO/VAP-1 inhibitor, which is near completion of a Phase I clinical trial.^[1]Eccogene wechat official accounts: https://mp.weixin.qq.com/s/WXukndw10XEoTvWIZgn5FQ
• Other pipelines includeds Small molecule Treg with is related to Autoimmune indications, and Exploratory Programs for Metabolic and Immunological indications.